IL4R and colorectal cancer: Francipane et al. reported that co-administration of an IL-4Rα antagonist or an IL-4 neutralizing antibody significantly and durably improved the therapeutic efficacy of oxaliplatin and/or 5-fluorouracil in mice bearing human colorectal cancer spheroids enriched with CSCs [66,67].